Multi-Cancer Blood Test Screening: From Laboratory Promise to Population Health Reality | iMedic

Why Do Most Cancers Lack a Screening Test?

Of the more than 200 recognized cancer types, only a handful have established population screening programs supported by randomized trial evidence of mortality reduction. Breast cancer (mammography), colorectal cancer (colonoscopy or stool-based tests), cervical cancer (Pap smear and HPV testing), and lung cancer (low-dose CT in high-risk smokers) represent the major successes. For the vast majority of malignancies — including pancreatic, ovarian, liver, esophageal, and kidney cancers — no validated screening tool exists for average-risk populations.

The consequences are stark. Data from the Surveillance, Epidemiology, and End Results (SEER) program show that cancers diagnosed at a localized stage have a five-year relative survival rate exceeding 90% for many tumor types, while metastatic diagnoses often carry survival rates below 30%. Without screening, many aggressive cancers are only identified after symptoms develop, frequently at advanced stages when curative treatment options are limited. This detection gap has motivated the development of blood-based multi-cancer early detection platforms that could simultaneously monitor for signals from many tumor types.

The biological rationale rests on the observation that all tumors, regardless of anatomical origin, release molecular debris into the circulation as cancer cells proliferate and undergo apoptosis. Cell-free DNA fragments bearing tumor-specific epigenetic modifications — particularly aberrant methylation patterns — accumulate in plasma at levels that modern sequencing technologies can detect. By interrogating hundreds of thousands of methylation sites simultaneously, computational classifiers can not only identify the presence of a tumor-derived signal but also predict its anatomical source, guiding clinicians toward targeted diagnostic evaluation rather than unfocused whole-body workups.

What Did the PATHFINDER Study Reveal About Real-World MCED Implementation?

While laboratory validation studies establish analytical performance, the PATHFINDER study — published in The Lancet in 2023 — was specifically designed to evaluate how an MCED test functions within actual clinical workflows. Conducted across seven U.S. sites, the study enrolled 6,662 adults aged 50 and older and assessed the diagnostic journey from a positive blood test result through to definitive cancer diagnosis or resolution. This pragmatic design addressed a concern that laboratory sensitivity figures alone cannot answer: what happens to patients after they receive a positive screening result?

Among participants, 1.4% received a "Cancer Signal Detected" result. Of those, approximately 38% were ultimately diagnosed with a confirmed malignancy. The median time from blood draw to diagnostic resolution was 79 days, and most evaluations required only standard-of-care diagnostic procedures such as imaging (CT, MRI, PET-CT) and tissue biopsy. Crucially, the tissue of origin prediction helped narrow diagnostic investigations, with physicians reporting that the predicted location guided their workup strategy in the majority of cases. Only a small fraction of patients required extensive multi-organ evaluation.

The study also illuminated challenges. Some participants with a cancer signal detected underwent multiple procedures before a malignancy was confirmed or the signal was deemed a false positive. The psychological burden of a positive screening result — even when ultimately resolved as benign — was noted as an area requiring careful patient counseling and support infrastructure. Additionally, PATHFINDER participants were predominantly white and commercially insured, raising questions about whether the diagnostic resolution experience would be comparable in more diverse populations with variable access to subspecialty care and advanced imaging.

How Could MCED Testing Affect Health System Capacity and Equity?

Health system readiness is among the most critical and least discussed aspects of MCED implementation. Modeling studies suggest that if a test like Galleri were offered annually to all adults aged 50-79 in a health system, even with its high specificity of 99.5%, the absolute number of individuals requiring diagnostic workup would be substantial given the large screening population. A 2024 analysis published in the Journal of Clinical Oncology estimated that implementing MCED testing across the eligible U.S. population could generate hundreds of thousands of additional PET-CT scans, specialist consultations, and tissue biopsies annually.

The downstream resource implications extend beyond radiology and pathology. Navigating patients through a diagnostic odyssey — particularly when the cancer signal origin points to organ systems where tissue sampling is invasive (such as pancreatic or brain biopsies) — requires multidisciplinary coordination. Health systems already facing workforce shortages in oncology, radiology, and gastroenterology would need to plan capacity expansions well before widespread MCED adoption.

Equity considerations compound these logistical challenges. Cancer outcomes already vary dramatically by socioeconomic status, race, and geographic access to care. If MCED testing becomes available primarily through self-pay or commercial insurance channels before public coverage decisions are made, there is a risk that the populations with the highest cancer mortality burden — often those with least access to subspecialty care — will be the last to benefit. Health policy researchers have emphasized that implementation strategies must proactively address these disparities, potentially through integration with community health centers, mobile phlebotomy programs, and streamlined referral networks for under-resourced areas.

What Are the Regulatory and Cost-Effectiveness Hurdles for MCED Approval?

Traditional regulatory pathways for cancer screening tests were designed for single-cancer, single-organ assays. Multi-cancer early detection tests present novel regulatory challenges because they simultaneously screen for dozens of malignancies with varying sensitivities, and because the clinical utility of detecting each cancer type may differ. The U.S. FDA granted Breakthrough Device Designation to the Galleri test, creating an expedited review pathway, but the agency has signaled that premarket approval will require robust evidence not just of analytical validity but of clinical utility — demonstrating that detection leads to meaningful changes in patient management and outcomes.

In parallel, the U.S. Congress has considered legislation — including proposed versions of the Multi-Cancer Early Detection Screening Coverage Act — that would create a Medicare coverage pathway for FDA-approved MCED tests. Coverage decisions will likely hinge on cost-effectiveness analyses. At a current self-pay price point near $949 per test, annual screening of tens of millions of eligible adults would represent a substantial expenditure. Preliminary health economic models have produced varied results depending on assumptions about test sensitivity improvements over time, the value assigned to earlier-stage diagnosis, treatment cost offsets from avoiding late-stage therapy, and the population age range targeted for screening.

The UK's approach through the NHS-Galleri trial offers a contrasting regulatory philosophy — generating real-world evidence within a national health system before making coverage decisions. With approximately 140,000 participants randomized to screening versus usual care, the trial is powered to detect a meaningful stage shift in cancer diagnoses. If positive results emerge from long-term follow-up, the NHS could become one of the first health systems globally to integrate MCED testing into a publicly funded screening program, providing a model for other universal health coverage systems evaluating this technology.